MX2022014618A - Protocolo mejorado para tratamiento de nefritis lupica. - Google Patents

Protocolo mejorado para tratamiento de nefritis lupica.

Info

Publication number
MX2022014618A
MX2022014618A MX2022014618A MX2022014618A MX2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A
Authority
MX
Mexico
Prior art keywords
treatment
lupus nephritis
improved protocol
protocol
improved
Prior art date
Application number
MX2022014618A
Other languages
English (en)
Spanish (es)
Inventor
Neil Solomons
Robert B Huizinga
Original Assignee
Aurinia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64095925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022014618(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aurinia Pharmaceuticals Inc filed Critical Aurinia Pharmaceuticals Inc
Publication of MX2022014618A publication Critical patent/MX2022014618A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
MX2022014618A 2017-05-12 2019-11-08 Protocolo mejorado para tratamiento de nefritis lupica. MX2022014618A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505734P 2017-05-12 2017-05-12
US201762541612P 2017-08-04 2017-08-04
US15/835,219 US10286036B2 (en) 2017-05-12 2017-12-07 Protocol for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
MX2022014618A true MX2022014618A (es) 2023-01-30

Family

ID=64095925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014618A MX2022014618A (es) 2017-05-12 2019-11-08 Protocolo mejorado para tratamiento de nefritis lupica.

Country Status (26)

Country Link
US (1) US10286036B2 (de)
EP (2) EP4257138A3 (de)
JP (4) JP7050904B2 (de)
KR (2) KR102710584B1 (de)
CN (1) CN111163794A (de)
AU (2) AU2018266850B2 (de)
BR (1) BR112019023766A2 (de)
CA (1) CA3063040A1 (de)
CL (1) CL2019003249A1 (de)
DK (1) DK3634463T3 (de)
ES (1) ES2965454T3 (de)
FI (1) FI3634463T3 (de)
HR (1) HRP20231469T1 (de)
HU (1) HUE064984T2 (de)
IL (2) IL310731A (de)
LT (1) LT3634463T (de)
MX (1) MX2022014618A (de)
MY (1) MY203070A (de)
NZ (2) NZ799751A (de)
PL (1) PL3634463T3 (de)
PT (1) PT3634463T (de)
RS (1) RS64959B1 (de)
SI (1) SI3634463T1 (de)
SM (1) SMT202300407T1 (de)
WO (1) WO2018207026A2 (de)
ZA (1) ZA201907460B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
KR20230147069A (ko) * 2021-01-15 2023-10-20 아우리니아 파마슈티컬스 인크. 칼시뉴린 억제제 신독성을 최소화하는 프로토콜
WO2022234439A1 (en) * 2021-05-04 2022-11-10 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
IT202300028041A1 (it) * 2023-12-27 2025-06-27 Indena Spa Processo per la preparazione di voclosporina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
ES2310604T3 (es) 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
EP2116228A1 (de) 2001-10-19 2009-11-11 Isotechnika Inc. Neuartige Cyclosporinanalog-Mikroemulsionspräkonzentrate
WO2003033526A2 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
SI1868635T1 (sl) 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
ES2532333T3 (es) * 2009-04-27 2015-03-26 Niigata University Uso de megalina en orina como marcador para la detección de nefropatía por IgA
US9679115B2 (en) 2010-02-02 2017-06-13 Kathrine P. Frey Methods and devices for reducing transfusions during or after surgery and for improving quality of life and function in chronic disease
EP2767276B1 (de) * 2011-10-12 2018-10-03 SBI Pharmaceuticals Co., Ltd. Mittel zur verbesserung/prophylaxe von chronischer nierenerkrankung
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Also Published As

Publication number Publication date
JP7050904B2 (ja) 2022-04-08
BR112019023766A2 (pt) 2020-05-26
EP4257138A3 (de) 2024-01-03
ZA201907460B (en) 2020-11-25
JP2025163248A (ja) 2025-10-28
US10286036B2 (en) 2019-05-14
JP7295305B2 (ja) 2023-06-20
PT3634463T (pt) 2023-12-05
IL270552A (en) 2020-01-30
JP2022095754A (ja) 2022-06-28
FI3634463T3 (fi) 2023-11-16
AU2018266850A2 (en) 2020-02-06
NZ759886A (en) 2026-01-30
RU2019140834A3 (de) 2021-08-25
RS64959B1 (sr) 2024-01-31
KR20240142619A (ko) 2024-09-30
AU2024202977A1 (en) 2024-05-23
CN111163794A (zh) 2020-05-15
CA3063040A1 (en) 2018-11-15
NZ799751A (en) 2026-01-30
ES2965454T3 (es) 2024-04-15
EP3634463B9 (de) 2024-01-10
RU2019140834A (ru) 2021-06-15
CL2019003249A1 (es) 2020-07-10
HRP20231469T1 (hr) 2024-03-01
IL270552B2 (en) 2024-07-01
MY203070A (en) 2024-06-06
SMT202300407T1 (it) 2024-01-10
KR102710584B1 (ko) 2024-09-27
EP3634463A2 (de) 2020-04-15
IL310731A (en) 2024-04-01
AU2018266850B2 (en) 2024-02-08
HUE064984T2 (hu) 2024-04-28
PL3634463T3 (pl) 2024-03-04
AU2018266850A1 (en) 2020-01-02
EP3634463B1 (de) 2023-09-27
DK3634463T3 (da) 2023-11-27
JP2020519695A (ja) 2020-07-02
EP4257138A2 (de) 2023-10-11
SI3634463T1 (sl) 2024-04-30
WO2018207026A3 (en) 2019-02-07
JP2023113884A (ja) 2023-08-16
EP3634463A4 (de) 2021-03-17
IL270552B1 (en) 2024-03-01
KR20200007884A (ko) 2020-01-22
WO2018207026A2 (en) 2018-11-15
LT3634463T (lt) 2024-01-10
US20180325995A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CL2019003249A1 (es) Protocolo mejorado para el tratamiento de nefritis lúpica.
CY1125170T1 (el) Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1
LT4021901T (lt) Pakeistieji piridopirimidinonilo junginiai, naudotini kaip t ląstelių aktyvatoriai
CO2020014586A2 (es) Compuestos
UY36275A (es) Compuestos aminopirimidinilo
MX378735B (es) Moduladores de receptores de quimiocina
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MA49545B1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
CL2017002456A1 (es) Composiciones y métodos para el tratamiento de la anemia.
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
SI4055021T1 (sl) Heterociklične spojine, ki inhibirajo rip1
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
MA41481B1 (fr) Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif
CL2019002353S1 (es) Scooter.
PE20240651A1 (es) Sintesis de indazoles
CL2018000508S1 (es) Cubierta posterior para moto scooter.
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
CL2019001522A1 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CL2018000290A1 (es) Antagonistas del receptor de cgrp
TWD178776S (zh) 行李箱(一)